BR112022005909A2 - ISOLATED ANTIBODIES OR ANTIGEN-BINDING FRAGMENT THEREOF, METHOD OF PREPARATION AND USES THEREOF, NUCLEOTIDE COMPOSITION, VECTOR, HOST CELL, PHARMACEUTICAL COMPOSITION, REAGENT FOR THE DETECTION OF LIF IN BIOLOGICAL SAMPLES, AND EXVIVO METHOD TO DETECT LIF IN BIOSPECIMEN - Google Patents

ISOLATED ANTIBODIES OR ANTIGEN-BINDING FRAGMENT THEREOF, METHOD OF PREPARATION AND USES THEREOF, NUCLEOTIDE COMPOSITION, VECTOR, HOST CELL, PHARMACEUTICAL COMPOSITION, REAGENT FOR THE DETECTION OF LIF IN BIOLOGICAL SAMPLES, AND EXVIVO METHOD TO DETECT LIF IN BIOSPECIMEN

Info

Publication number
BR112022005909A2
BR112022005909A2 BR112022005909A BR112022005909A BR112022005909A2 BR 112022005909 A2 BR112022005909 A2 BR 112022005909A2 BR 112022005909 A BR112022005909 A BR 112022005909A BR 112022005909 A BR112022005909 A BR 112022005909A BR 112022005909 A2 BR112022005909 A2 BR 112022005909A2
Authority
BR
Brazil
Prior art keywords
lif
antigen
binding fragment
reagent
vector
Prior art date
Application number
BR112022005909A
Other languages
Portuguese (pt)
Inventor
Liu Qinghao
Tao Jun
Zhou Wenlai
He Shanshan
Yang Haiyan
Wang Hongling
Yang Guiqun
Original Assignee
Jacobio Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jacobio Pharmaceuticals Co Ltd filed Critical Jacobio Pharmaceuticals Co Ltd
Publication of BR112022005909A2 publication Critical patent/BR112022005909A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

ANTICORPOS ISOLADOS OU FRAGMENTO DE LIGAÇÃO AO ANTÍGENO DOS MESMOS, USOS E MÉTODO DEPREPARAÇÃO DOS MESMOS, COMPOSIÇÃO NUCLEOTÍDICA, VETOR, CÉLULA HOSPEDEIRA, COMPOSIÇÃO FARMACÊUTICA, REAGENTE PARA DETECÇÃO DE LIF EM AMOSTRAS BIOLÓGICAS, E MÉTODO EX-VIVO PARA DETECTAR O LIF EM AMOSTRAS BIOLÓGICAS. É fornecida uma molécula de ligação específica para LIF e seu uso. Especificamente, é fornecido um anticorpo isolado ou um fragmento de ligação ao antígeno do mesmo que se liga ao LIF e inibe a atividade do LIF. Também são fornecidas as utilizações do anticorpo isolado ou do fragmento de ligação ao antígeno do mesmo no tratamento de doenças.ISOLATED ANTIBODIES OR ANTIGEN BINDING FRAGMENT THEREOF, USES AND METHOD OF PREPARATION THEREOF, NUCLEOTIDE COMPOSITION, VECTOR, HOST CELL, PHARMACEUTICAL COMPOSITION, REAGENT FOR DETECTION OF LIF IN BIOLOGICAL SAMPLES, AND EX-VIVO METHOD TO DETECT LIFBI IN SAMPLES . A specific binding molecule for LIF and its use is provided. Specifically, an isolated antibody or an antigen-binding fragment thereof that binds to LIF and inhibits the activity of LIF is provided. Also provided are uses of the isolated antibody or antigen-binding fragment thereof in the treatment of diseases.

BR112022005909A 2019-09-29 2020-09-28 ISOLATED ANTIBODIES OR ANTIGEN-BINDING FRAGMENT THEREOF, METHOD OF PREPARATION AND USES THEREOF, NUCLEOTIDE COMPOSITION, VECTOR, HOST CELL, PHARMACEUTICAL COMPOSITION, REAGENT FOR THE DETECTION OF LIF IN BIOLOGICAL SAMPLES, AND EXVIVO METHOD TO DETECT LIF IN BIOSPECIMEN BR112022005909A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019108904 2019-09-29
CN2020077049 2020-02-27
PCT/CN2020/118247 WO2021057991A1 (en) 2019-09-29 2020-09-28 Binding molecule specific for lif and use thereof

Publications (1)

Publication Number Publication Date
BR112022005909A2 true BR112022005909A2 (en) 2022-10-11

Family

ID=75165589

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022005909A BR112022005909A2 (en) 2019-09-29 2020-09-28 ISOLATED ANTIBODIES OR ANTIGEN-BINDING FRAGMENT THEREOF, METHOD OF PREPARATION AND USES THEREOF, NUCLEOTIDE COMPOSITION, VECTOR, HOST CELL, PHARMACEUTICAL COMPOSITION, REAGENT FOR THE DETECTION OF LIF IN BIOLOGICAL SAMPLES, AND EXVIVO METHOD TO DETECT LIF IN BIOSPECIMEN

Country Status (13)

Country Link
US (1) US20210403582A1 (en)
EP (1) EP4036114A4 (en)
JP (1) JP2022550121A (en)
KR (1) KR20220087457A (en)
CN (1) CN114040924A (en)
AU (1) AU2020354255A1 (en)
BR (1) BR112022005909A2 (en)
CA (1) CA3156080A1 (en)
CL (1) CL2022000752A1 (en)
IL (1) IL291710A (en)
MX (1) MX2022003762A (en)
TW (1) TWI770619B (en)
WO (1) WO2021057991A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022228514A1 (en) * 2021-04-29 2022-11-03 北京浩古元方生物医药科技有限公司 Anti-human leukemia inhibitory factor antibody and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3720353B2 (en) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル Multivalent and multispecific binding proteins, their production and use
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JP4213224B2 (en) 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド Method for producing multispecific antibody having heteromultimer and common component
US8039218B2 (en) * 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
AU2005282700A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
EP1872124A4 (en) * 2005-04-19 2008-06-11 Prediction Sciences Llc Diagnostic markers of breast cancer treatment and progression and methods of use thereof
US20080280297A1 (en) * 2005-07-15 2008-11-13 The Trustees Of Columbia University In The City Of Compositions and Methods for Differential Diagnosis of Chronic Lymphocytic Leukemia
US20120178111A1 (en) * 2009-09-23 2012-07-12 Diamandis Eleftherios P Methods and compositions for the detection of lung cancers
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
TW201623329A (en) * 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 Vaccines and monoclonal antibodies targeting truncated variants of osteopontin and uses thereof
EP3173483A1 (en) * 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation
US10583191B2 (en) * 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
EP3806960A1 (en) * 2018-06-18 2021-04-21 MedImmune Limited Methods of quantifying lif and uses thereof

Also Published As

Publication number Publication date
EP4036114A1 (en) 2022-08-03
EP4036114A4 (en) 2023-11-08
JP2022550121A (en) 2022-11-30
IL291710A (en) 2022-05-01
CN114040924A (en) 2022-02-11
MX2022003762A (en) 2022-06-24
TW202112813A (en) 2021-04-01
KR20220087457A (en) 2022-06-24
CL2022000752A1 (en) 2022-11-18
CA3156080A1 (en) 2021-04-01
TWI770619B (en) 2022-07-11
AU2020354255A1 (en) 2022-04-21
WO2021057991A1 (en) 2021-04-01
US20210403582A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
CY1123708T1 (en) ANTIBODIES THAT BIND TO HUMAN PROGRAMMED DEATH LINKER 1 (PD-L1)
BR112018016337A2 (en) monoclonal antibodies to antidengue virus protein ns1
BR112022015450A2 (en) ISOLATED MONOCLONAL ANTIBODY OR CONNECTION FRAGMENT TO ITS ANTIGEN, PHARMACEUTICAL COMPOSITION, ISOLATED NUCLEIC ACID, VECTOR, HOST CELL, PROCESS OF PRODUCTION OF AN ANTIBODY, CHIMERIC ANTIGEN RECEPTOR PROTEIN (CAR), MODIFIED CELL, METHOD FOR TREATMENT OR IMPROVEMENT OF A CANCER IN A SUBJECT, A METHOD TO ENHANCE THE ACTIVATION OF T CELLS IN A SUBJECT AND A METHOD TO MODULATE THE M2A MACROPHAGE PHENOTYPE IN A SUBJECT
BR112019011186A2 (en) radiolabeled antibody conjugate, compound, and methods of imaging and for treating a tumor.
BR112016014284A2 (en) isolated caninized antibody or antigen binding fragment thereof, isolated nucleic acid, expression vector, host cell, pharmaceutical composition, and methods for enhancing the activity of an immune cell and for producing a caninized antibody or antigen binding fragment the same
BR112013004579A2 (en) mmp9 binding protein, nucleic acid, vector, cell, pharmaceutical composition and its use as well as mmp9 expression detection method
Paluch et al. Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing
BRPI0618399A2 (en) isolated antigen binding region that is specific for cd38, isolated antibody or a functional fragment thereof that is specific for cd38, isolated antibody or a functional fragment thereof, isolated immunoglobulin, heavy chain variable of an isolated antigen binding region, variable light chain from an isolated antigen binding region, isolated nucleic acid sequence, nucleic acid sequence encoding a variable heavy chain from an isolated antigen binding region, nucleic acid sequence, vector, isolated cell, pharmaceutical composition, use of the pharmaceutical composition, method of inducing specific death of cd38-expressing tumor cells, method of detecting specific death of cd38-expressing tumor cells, method of detecting the presence of cd38 in a minipore source tissue or cell , cd38 detection method in a cd3-expressing erythrocyte 8 and diagnostic composition
BR112017020915A2 (en) isolated mammalian antibody or antigen-binding fragment thereof, caninized antibody or caninized antigen binding fragment thereof, caninized monoclonal antibody or antigen-binding fragment thereof, isolated nucleic acid, expression vector, host cell, peptide isolated, fusion protein, pharmaceutical composition, and method for decreasing the activity of an immune cell?
BRPI0610092B8 (en) methods for detecting an analyte and nucleic acid in a sample, and synthesizing a nucleic acid or nucleic acid analogue molecule, reagent kit, use thereof, nucleic acid or nucleic acid analogue molecule, and associated product
ES2711398T3 (en) Procedure to reduce false negatives in immunoassay to test sample derived from biomembrane
BR112015022844A8 (en) method to determine the presence or absence of donor-specific antibodies in a biological sample, system and kit to practice the same
Okun et al. Affinity capillary electrophoresis for the assessment of complex formation between viruses and monoclonal antibodies
BR112021009275A2 (en) Humanized anti-sirp alpha antibody or an antigen-binding fragment thereof, pharmaceutical composition, nucleic acid molecule, and host cell.
BR112022019129A2 (en) SIGLEC15 BINDING ANTIBODIES AND USES THEREOF
BR112022012474A2 (en) ANTI-LILRB1 ANTIBODY, ANTIGEN BINDING FRAGMENT THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING THEM, USE OF SUCH ANTIBODY TO TREAT OR PREVENT CANCER, METHOD OF PREPARING SUCH ANTIBODY, NUCLEIC ACID MOLECULE AND RECOMBINANT CELL AND VECTOR.
Semrad et al. Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results
BR112017011545A2 (en) indirect homogeneous mobility shift assay for detection of biological products in patient samples
BR112021024553A2 (en) Specific binding molecule for cd73 and use of binding molecule
BR112022005909A2 (en) ISOLATED ANTIBODIES OR ANTIGEN-BINDING FRAGMENT THEREOF, METHOD OF PREPARATION AND USES THEREOF, NUCLEOTIDE COMPOSITION, VECTOR, HOST CELL, PHARMACEUTICAL COMPOSITION, REAGENT FOR THE DETECTION OF LIF IN BIOLOGICAL SAMPLES, AND EXVIVO METHOD TO DETECT LIF IN BIOSPECIMEN
Li et al. A simple slot blot for the detection of virtually all subtypes of the influenza A viral hemagglutinins using universal antibodies targeting the fusion peptide
EA201370030A1 (en) BIFUNCTIONAL QUANTITATIVE IN VITRO ANALYSIS OF BINDING TARGETS FOR DETECTING NEUTRALIZING ANTIBODIES TO TARGET ANTIBODIES
BR112018075414A2 (en) method for detecting the presence of mycobacterial material in a sample using at least two antigens, solid substrate and biosensor
Mihara et al. Host cell proteins: the hidden side of biosimilarity assessment
BR112022022353A2 (en) COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING CD70-SPECIFIC FUSION PROTEINS